Shukra Pharma Skyrockets Revenue 270%, Profit 542%, But EPS Dips

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Shukra Pharma Skyrockets Revenue 270%, Profit 542%, But EPS Dips
Overview

Shukra Pharmaceuticals Limited has reported a blockbuster third quarter with revenue surging 270.74% year-on-year to ₹39.13 Cr and net profit soaring 542.75% to ₹20.36 Cr. PBT margins expanded significantly to 67.16%. However, Earnings Per Share (EPS) declined 34.72% to ₹0.47 due to a higher equity base. The company also re-appointed Dakshesh Shah as Managing Director for five years.

Shukra Pharmaceuticals Delivers Blockbuster Q3 Driven by Massive Revenue and Profit Growth

Shukra Pharmaceuticals Limited has announced exceptional financial results for the third quarter and nine months ended December 31, 2025, showcasing a dramatic surge in top-line and bottom-line figures.

📉 The Financial Deep Dive

The Numbers:

For the third quarter (Q3 FY26) compared to the same period last year (Q3 FY25):

  • Revenue from Operations witnessed an explosive growth of 270.74% YoY, reaching ₹3,913.48 Lakhs (₹39.13 Cr) from ₹1,058.43 Lakhs (₹10.58 Cr).

  • Profit Before Tax (PBT) skyrocketed by 555.09% YoY to ₹2,683.15 Lakhs (₹26.83 Cr), up from ₹409.49 Lakhs (₹4.09 Cr).

  • Net Profit (PAT) followed suit with a monumental increase of 542.75% YoY, soaring to ₹2,036.46 Lakhs (₹20.36 Cr) from ₹316.44 Lakhs (₹3.16 Cr).

For the nine-month period ended December 31, 2025 (9M FY26) versus 9M FY25:
  • Revenue from Operations grew by an impressive 161.00% YoY to ₹5,040.33 Lakhs from ₹1,931.75 Lakhs.

  • Net Profit (PAT) surged by 468.40% YoY to ₹2,377.46 Lakhs from ₹418.87 Lakhs.

The Quality:


  • Margin Expansion: The company demonstrated significant operational efficiency, with PBT margins improving substantially to 67.16% in Q3 FY26 from 35.33% in Q3 FY25. This indicates strong pricing power or cost control relative to revenue growth.

  • EPS Dilution: Despite the stellar profit growth, Earnings Per Share (EPS) decreased by 34.72% YoY to ₹0.47 from ₹0.72. This is explicitly attributed by the company to an increase in its paid-up equity share capital, which rose from ₹3,378.79 Lakhs to ₹4,378.79 Lakhs during the period. Investors should note this dilution effect.

No exceptional or extraordinary items were reported, suggesting the strong performance is driven by core operations. The company operates in a single segment, simplifying the analysis.

The Grill:

While the financial numbers are overwhelmingly positive, the significant year-on-year drop in EPS, despite massive profit growth, warrants investor attention. The company's explanation points to increased share capital, which could be due to a rights issue, preferential allotment, or ESOPs. Further details on the nature and purpose of this capital raise would be crucial for a complete understanding.

Other Key Developments:

The Board of Directors approved the re-appointment of Mr. Dakshesh Shah as Managing Director for a period of five years, effective December 30, 2025. This signals continuity in leadership. The statutory auditors have provided an unqualified audit report on the financial results, adding a layer of assurance.

---

Impact: This news is highly positive for Shukra Pharmaceuticals' top and bottom lines, signalling strong operational momentum. The massive margin expansion is a key highlight. However, the EPS dilution due to increased share capital could temper investor enthusiasm if not accompanied by a clear strategic benefit or future growth visibility from the capital raise. The unqualified audit report and MD re-appointment are governance positives.

Rating: 8/10 - Significant financial performance, with a key detail (EPS dilution) requiring further investor scrutiny.

Terms Explained:

  • PBT (Profit Before Tax): Profit earned by a company before deducting income tax expenses.

  • PAT (Profit After Tax): Also known as Net Profit, it is the profit remaining after all expenses, including taxes, have been deducted.

  • EPS (Earnings Per Share): A company's net profit divided by the number of outstanding shares of common stock. A lower EPS despite higher profit means more shares are outstanding.

  • YoY (Year-on-Year): Comparison of a period with the same period in the previous year.

  • Lakhs/Crore: Indian units of currency. 1 Lakh = 100,000; 1 Crore = 10,000,000. 1 Crore = 100 Lakhs.

  • Unqualified Audit Report: An auditor's opinion stating that the financial statements are presented fairly and in accordance with accounting standards, with no significant exceptions.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.